Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy

Luigi M. Specchio, Giovanni Boero, Nicola Specchio, Giusi De Agazio, Alessia De Palo, Marina de Tommaso, Ettore Beghi, Angela La Neve

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The objective of this observational study was to compare the efficacy of levetiracetam and topiramate during the first 15 days of add-on treatment in adults with refractory partial epilepsy. Two cohorts of patients with ≥3 simple or complex partial seizures with or without secondary generalisation per month over an 8-week baseline period received levetiracetam or topiramate in two distinct phases, in addition to standard antiepileptic treatment. During the first 15 days of the therapy, levetiracetam was added at the dosage of 250 mg b.i.d. or topiramate at 25 mg o.i.d. Efficacy parameters included number of seizure-free days (SFDs), mean and percent reduction in seizure frequency (in general and by type), and number of seizure-free patients in the first 15 days of treatment compared to last 15 days of the baseline period. Sixty-one patients received levetiracetam and 61 topiramate. The general characteristics of the two treatment groups were similar. The total number of SFDs during 15 days before treatment was 637 with levetiracetam and 621 with topiramate; in the 15-day evaluation period the SFDs increased to 748 (17.4%) and 668 (7.6%), respectively (ANOVA, p <0.05). Twenty-six patients (42.6%) taking levetiracetam were seizure free compared to 10 (16.4%) receiving topiramate (chi-square, p = 0.003). This open-label non-controlled study suggests an early efficacy of levetiracetam as add-on therapy in patients with refractory partial epilepsy: These results appear to confirm previous indications of a rapid onset of action and seem to suggest first evaluation of the patient at the dose of 500 mg/day before increasing to the considered minimum standard dose of 1000 mg/day, as some patients could respond to the starting dose.

Original languageEnglish
Pages (from-to)112-116
Number of pages5
JournalSeizure
Volume15
Issue number2
DOIs
Publication statusPublished - Mar 2006

Fingerprint

etiracetam
Partial Epilepsy
Seizures
Therapeutics
topiramate
Anticonvulsants
Observational Studies

Keywords

  • Levetiracetam
  • Rapid onset action
  • Refractory partial epilepsy
  • Seizure-free days
  • Topiramate

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Psychology(all)

Cite this

Specchio, L. M., Boero, G., Specchio, N., De Agazio, G., De Palo, A., de Tommaso, M., ... La Neve, A. (2006). Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy. Seizure, 15(2), 112-116. https://doi.org/10.1016/j.seizure.2005.11.006

Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy. / Specchio, Luigi M.; Boero, Giovanni; Specchio, Nicola; De Agazio, Giusi; De Palo, Alessia; de Tommaso, Marina; Beghi, Ettore; La Neve, Angela.

In: Seizure, Vol. 15, No. 2, 03.2006, p. 112-116.

Research output: Contribution to journalArticle

Specchio, LM, Boero, G, Specchio, N, De Agazio, G, De Palo, A, de Tommaso, M, Beghi, E & La Neve, A 2006, 'Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy', Seizure, vol. 15, no. 2, pp. 112-116. https://doi.org/10.1016/j.seizure.2005.11.006
Specchio, Luigi M. ; Boero, Giovanni ; Specchio, Nicola ; De Agazio, Giusi ; De Palo, Alessia ; de Tommaso, Marina ; Beghi, Ettore ; La Neve, Angela. / Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy. In: Seizure. 2006 ; Vol. 15, No. 2. pp. 112-116.
@article{2f1fa8a94d344d80b148de1d0e2b243f,
title = "Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy",
abstract = "The objective of this observational study was to compare the efficacy of levetiracetam and topiramate during the first 15 days of add-on treatment in adults with refractory partial epilepsy. Two cohorts of patients with ≥3 simple or complex partial seizures with or without secondary generalisation per month over an 8-week baseline period received levetiracetam or topiramate in two distinct phases, in addition to standard antiepileptic treatment. During the first 15 days of the therapy, levetiracetam was added at the dosage of 250 mg b.i.d. or topiramate at 25 mg o.i.d. Efficacy parameters included number of seizure-free days (SFDs), mean and percent reduction in seizure frequency (in general and by type), and number of seizure-free patients in the first 15 days of treatment compared to last 15 days of the baseline period. Sixty-one patients received levetiracetam and 61 topiramate. The general characteristics of the two treatment groups were similar. The total number of SFDs during 15 days before treatment was 637 with levetiracetam and 621 with topiramate; in the 15-day evaluation period the SFDs increased to 748 (17.4{\%}) and 668 (7.6{\%}), respectively (ANOVA, p <0.05). Twenty-six patients (42.6{\%}) taking levetiracetam were seizure free compared to 10 (16.4{\%}) receiving topiramate (chi-square, p = 0.003). This open-label non-controlled study suggests an early efficacy of levetiracetam as add-on therapy in patients with refractory partial epilepsy: These results appear to confirm previous indications of a rapid onset of action and seem to suggest first evaluation of the patient at the dose of 500 mg/day before increasing to the considered minimum standard dose of 1000 mg/day, as some patients could respond to the starting dose.",
keywords = "Levetiracetam, Rapid onset action, Refractory partial epilepsy, Seizure-free days, Topiramate",
author = "Specchio, {Luigi M.} and Giovanni Boero and Nicola Specchio and {De Agazio}, Giusi and {De Palo}, Alessia and {de Tommaso}, Marina and Ettore Beghi and {La Neve}, Angela",
year = "2006",
month = "3",
doi = "10.1016/j.seizure.2005.11.006",
language = "English",
volume = "15",
pages = "112--116",
journal = "Seizure : the journal of the British Epilepsy Association",
issn = "1059-1311",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy

AU - Specchio, Luigi M.

AU - Boero, Giovanni

AU - Specchio, Nicola

AU - De Agazio, Giusi

AU - De Palo, Alessia

AU - de Tommaso, Marina

AU - Beghi, Ettore

AU - La Neve, Angela

PY - 2006/3

Y1 - 2006/3

N2 - The objective of this observational study was to compare the efficacy of levetiracetam and topiramate during the first 15 days of add-on treatment in adults with refractory partial epilepsy. Two cohorts of patients with ≥3 simple or complex partial seizures with or without secondary generalisation per month over an 8-week baseline period received levetiracetam or topiramate in two distinct phases, in addition to standard antiepileptic treatment. During the first 15 days of the therapy, levetiracetam was added at the dosage of 250 mg b.i.d. or topiramate at 25 mg o.i.d. Efficacy parameters included number of seizure-free days (SFDs), mean and percent reduction in seizure frequency (in general and by type), and number of seizure-free patients in the first 15 days of treatment compared to last 15 days of the baseline period. Sixty-one patients received levetiracetam and 61 topiramate. The general characteristics of the two treatment groups were similar. The total number of SFDs during 15 days before treatment was 637 with levetiracetam and 621 with topiramate; in the 15-day evaluation period the SFDs increased to 748 (17.4%) and 668 (7.6%), respectively (ANOVA, p <0.05). Twenty-six patients (42.6%) taking levetiracetam were seizure free compared to 10 (16.4%) receiving topiramate (chi-square, p = 0.003). This open-label non-controlled study suggests an early efficacy of levetiracetam as add-on therapy in patients with refractory partial epilepsy: These results appear to confirm previous indications of a rapid onset of action and seem to suggest first evaluation of the patient at the dose of 500 mg/day before increasing to the considered minimum standard dose of 1000 mg/day, as some patients could respond to the starting dose.

AB - The objective of this observational study was to compare the efficacy of levetiracetam and topiramate during the first 15 days of add-on treatment in adults with refractory partial epilepsy. Two cohorts of patients with ≥3 simple or complex partial seizures with or without secondary generalisation per month over an 8-week baseline period received levetiracetam or topiramate in two distinct phases, in addition to standard antiepileptic treatment. During the first 15 days of the therapy, levetiracetam was added at the dosage of 250 mg b.i.d. or topiramate at 25 mg o.i.d. Efficacy parameters included number of seizure-free days (SFDs), mean and percent reduction in seizure frequency (in general and by type), and number of seizure-free patients in the first 15 days of treatment compared to last 15 days of the baseline period. Sixty-one patients received levetiracetam and 61 topiramate. The general characteristics of the two treatment groups were similar. The total number of SFDs during 15 days before treatment was 637 with levetiracetam and 621 with topiramate; in the 15-day evaluation period the SFDs increased to 748 (17.4%) and 668 (7.6%), respectively (ANOVA, p <0.05). Twenty-six patients (42.6%) taking levetiracetam were seizure free compared to 10 (16.4%) receiving topiramate (chi-square, p = 0.003). This open-label non-controlled study suggests an early efficacy of levetiracetam as add-on therapy in patients with refractory partial epilepsy: These results appear to confirm previous indications of a rapid onset of action and seem to suggest first evaluation of the patient at the dose of 500 mg/day before increasing to the considered minimum standard dose of 1000 mg/day, as some patients could respond to the starting dose.

KW - Levetiracetam

KW - Rapid onset action

KW - Refractory partial epilepsy

KW - Seizure-free days

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=32044436507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044436507&partnerID=8YFLogxK

U2 - 10.1016/j.seizure.2005.11.006

DO - 10.1016/j.seizure.2005.11.006

M3 - Article

C2 - 16406697

AN - SCOPUS:32044436507

VL - 15

SP - 112

EP - 116

JO - Seizure : the journal of the British Epilepsy Association

JF - Seizure : the journal of the British Epilepsy Association

SN - 1059-1311

IS - 2

ER -